IFP Advisors’s Standard BioTools LAB Stock Holding History

IFP Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$292	Sell	318 -471	-60%	-$570	﹤0.01%	4542
2025 Q4	$1.01K	Hold	789	–	–	﹤0.01%	4069
2025 Q3	$1.03K	Sell	789 -30	-4%	-$39	﹤0.01%	3955
2025 Q2	$982	Buy	+819	New	+$908	﹤0.01%	4233
2025 Q1	–	Sell	-7	Closed	-$12	–	4502
2024 Q4	$12	Buy	+7	New	+$13	﹤0.01%	4517
2023 Q1	–	Sell	-1,527	Closed	-$9K	–	3977
2022 Q4	$9K	Sell	1,527 -401	-21%	-$494	﹤0.01%	3457
2022 Q3	$11K	Sell	1,928 -609	-24%	-$921	﹤0.01%	3584
2022 Q2	$14K	Hold	2,537	–	–	﹤0.01%	3148
2022 Q1	$14K	Buy	+2,537	New	+$8.76K	﹤0.01%	3148

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

IFP Advisors's LAB Position: Q1 2026 in Review

IFP Advisors reduced its Standard BioTools (LAB) stake by 60% in Q1 2026, selling an estimated $570 and leaving 318 shares worth $292. The position accounts for ﹤0.01% of the portfolio, ranked #4542.

IFP Advisors first reported a position in LAB in Q1 2022 and has held it in 9 quarters since. The position peaked at $14K in Q2 2022. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

IFP Advisors held 318 shares of Standard BioTools worth $292 as of Q1 2026.
IFP Advisors sold 471 Standard BioTools shares in Q1 2026, an estimated $570.
Standard BioTools made up ﹤0.01% of IFP Advisors's portfolio in Q1 2026, its #4542 holding.
IFP Advisors first reported a position in Standard BioTools in Q1 2022 and has held it in 9 quarters since.
IFP Advisors's Standard BioTools position peaked at $14K in Q2 2022.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.